Entries by CAPTIS

Eli Lilly gets FDA approval for migraine drug Reyvow

Reyvow is a new oral medication for the acute treatment of migraine, with or without aura, in adults. It binds to 5-HT1F receptors with high affinity. Reyvow is The post Eli Lilly gets FDA approval for migraine drug Reyvow appeared first on Pharmaceutical Business review.

Gilead, Galapagos announce 52-week results of filgotinib in FINCH 1, FINCH 3 studies in rheumatoid arthritis

“We are encouraged by the durability of both the efficacy and safety profiles of filgotinib seen in these studies,” said John Sundy, MD, PhD, Senior Vice President, Inflammation The post Gilead, Galapagos announce 52-week results of filgotinib in FINCH 1, FINCH 3 studies in rheumatoid arthritis appeared first on Pharmaceutical Business review.

Belgium’s UCB to buy Ra Pharmaceuticals for $ 2.1bn

Under the deal, Ra Pharmaceuticals shareholders will secure $48 in cash for each of its share at closing. Based in Cambridge of Massachusetts, Ra Pharma uses an advanced The post Belgium’s UCB to buy Ra Pharmaceuticals for $ 2.1bn appeared first on Pharmaceutical Business review.

Alexion, Stealth announce agreement for option to co-develop and commercialise late-stage therapy for mitochondrial diseases

Currently being evaluated in a Phase 3 study in people with primary mitochondrial myopathy (PMM) – a genetic mitochondrial disease – elamipretide is a novel, potential first-in-class therapy The post Alexion, Stealth announce agreement for option to co-develop and commercialise late-stage therapy for mitochondrial diseases appeared first on Pharmaceutical Business review.